| Original language | English (US) |
|---|---|
| Pages (from-to) | 1162-1164 |
| Number of pages | 3 |
| Journal | Journal of the American Academy of Dermatology |
| Volume | 84 |
| Issue number | 4 |
| DOIs | |
| State | Published - Apr 2021 |
ASJC Scopus subject areas
- Dermatology
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Journal of the American Academy of Dermatology, Vol. 84, No. 4, 04.2021, p. 1162-1164.
Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Efficacy of sonidegib in histologic subtypes of advanced basal cell carcinoma
T2 - Results from the final analysis of the randomized phase 2 Basal Cell Carcinoma Outcomes With LDE225 Treatment (BOLT) trial at 42 months
AU - Dummer, Reinhard
AU - Lear, John T.
AU - Guminski, Alex
AU - Leow, Liang Joo
AU - Squittieri, Nicholas
AU - Migden, Michael
N1 - Funding Information: Funding sources: This work was supported by Sun Pharmaceutical Industries, Inc.Conflicts of interest: Dr Dummer has received research funding from Bristol-Myers Squibb, MSD, Novartis Pharmaceuticals Corporation, Roche, and GlaxoSmithKline; and has served as a consultant or participated on an advisory board for Amgen; Bristol-Myers Squibb; MSD; Novartis Pharmaceuticals Corporation; Roche; GlaxoSmithKline; Sun Pharmaceutical Industries, Inc.; and Takeda. Dr Lear has served as a consultant or speaker for and received honoraria from Novartis Pharmaceuticals Corporation and travel support from Sun Pharmaceutical Industries, Inc. Dr Guminski has participated on advisory boards for Bristol-Myers Squibb, Pfizer, and Sanofi; received honoraria from Novartis Pharmaceuticals Corporation; and received travel support from Astellas and Bristol-Myers Squibb. Author Leow has participated on an advisory board for and received honoraria from Novartis Pharmaceuticals Corporation and has received travel support from Eli Lilly and Company; Janssen Pharmaceuticals; and Sun Pharmaceutical Industries, Inc. Dr Squittieri is an employee of Sun Pharmaceutical Industries, Inc. Dr Migden has participated on advisory boards and received honoraria from Eli Lilly and Company, Genentech Inc, Novartis Pharmaceuticals Corporation, and Regeneron; and has received consulting fees from Sun Pharmaceutical Industries, Inc. Funding Information: Funding sources: This work was supported by Sun Pharmaceutical Industries, Inc.
PY - 2021/4
Y1 - 2021/4
UR - http://www.scopus.com/inward/record.url?scp=85098204783&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85098204783&partnerID=8YFLogxK
U2 - 10.1016/j.jaad.2020.08.042
DO - 10.1016/j.jaad.2020.08.042
M3 - Article
C2 - 33358380
AN - SCOPUS:85098204783
SN - 0190-9622
VL - 84
SP - 1162
EP - 1164
JO - Journal of the American Academy of Dermatology
JF - Journal of the American Academy of Dermatology
IS - 4
ER -